Cellceutix Seeks FDA’s Advice on Ulcerative Proctitis Therapy

Cellceutix Seeks FDA’s Advice on Ulcerative Proctitis Therapy
Clinical stage biopharmaceutical company, Cellceutix Corporation, is submitting a request to the U.S. Food and Drug Administration (FDA) for a pre-Investigational New Drug (IND) meeting. The company, which is dedicated to developing novel treatments with oncology, dermatology and antimicrobial applications, aims to discuss the creation of a new topical defensin-mimetic compound as a therapy for ulcerative proctitis and ulcerative proctosigmoiditis. Cellceutix’ compound is expected

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *